Please ensure Javascript is enabled for purposes of website accessibility

Why Immunovant Stock Dropped Today

By Prosper Junior Bakiny - Feb 16, 2021 at 5:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors didn't respond well to the company's latest quarterly update.

What happened?

Shares of clinical-stage biopharmaceutical company Immunovant (IMVT 6.78%) plunged by 27.2% on Tuesday following the company's release of its financial results for the third quarter of its fiscal year 2021 that ended on Dec. 31. 

So what

There wasn't a lot of new or groundbreaking information in Immunovant's quarterly update. The company does not have any products on the market, and it does not generate any revenue. The drugmaker recorded a net loss of $31.8 million on the bottom line, or a loss of $0.32 on a per-share basis. On average, analysts expected the company to record a net loss per share of $0.26.

Could the bottom-line miss be the reason why Immunovant's stock lost altitude today? That seems unlikely: Investors don't care too much about the revenue and earnings of clinical-stage biopharmaceutical companies. Rather, regulatory updates and information regarding the progress of clinical trials are much more critical. 

Downward-bound graph on a blackboard.

Image source: Getty Images.

On that front, Immunovant did report some news today, although some of it was already known. As a reminder, the company recently announced that it had to temporarily halt a couple of clinical trials for IMVT-1401, a potential treatment for thyroid eye disease (TED). The decision came following recorded cases of elevated total cholesterol and LDL (a form of cholesterol that is potentially harmful) levels in patients treated with IMVT-1401.

Today, Immunovant announced that it alerted regulatory authorities of these developments. The company has started a comprehensive review of the data to better characterize the higher LDL levels observed in patients treated with IMVT-1401.

Now what

Today's quarterly update certainly could have been better for Immunovant. No doubt investors would have loved to hear that the company's clinical trials for IMVT-1401 were back on track. Perhaps that explains why Immunovant's shares dropped today. The healthcare company plans to continue the development of IMVT-1401, and it will provide another update in the second quarter of the current calendar year. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Immunovant, Inc. Stock Quote
Immunovant, Inc.
IMVT
$4.25 (6.78%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.